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Abstract
Background Adhesions lead to considerable patient
morbidity and are a mounting burden on surgeons and the
health care system alike. Although adhesion formation is
the most frequent complication in abdominal and pelvic
surgery, many surgeons are still not aware of the extent of
the problem. To provide the best care for their patients,
surgeons should consistently inform themselves of anti-
adhesion strategies and include these methods in their daily
routine.
Methods Searches were conducted in PubMed and The
Cochrane Library to identify relevant literature.
Findings Various complications are associated with
adhesion formation, including small bowel obstruction,
infertility and chronic pelvic pain. Increasingly, an under-
standing of adhesion formation as a complex process
inﬂuenced by many different factors has led to various
conceivable anti-adhesion strategies. At present, a number
of different anti-adhesion agents are available. Although
some agents have proved effective in reducing adhesion
formation in randomised controlled trials, none of them can
completely prevent adhesion formation.
Conclusion To fulﬁl our duty to provide best possible
care for our patients, it is now time to regard adhesions as
the most common complication in surgery. Further
research is needed to fully understand adhesion formation
and to develop new strategies for adhesion prevention.
Large clinical efﬁcacy trials of anti-adhesion agents will
make it easier for surgeons to decide which agent to use in
daily routine.
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Background
In abdominal and pelvic surgery, adhesion formation must
be regarded as the most common postsurgical complication
occurring after 60–90% of procedures [1, 2]. There is a
long list of adhesion-related consequences ranging from
small bowel obstruction (SBO) to considerable costs for the
health care system. In the past, the Surgical and Clinical
Adhesions Research studies (SCAR studies) demonstrated
that adhesions are an important issue for the patients and a
mounting burden on both the health care system and the
surgeons who are faced daily with the treatment of adhe-
sion-related complications [3–5].
In view of the importance of adhesions, more and more
research has been performed over the last decades, and our
understanding of the complexity of adhesion formation has
increased considerably. Investigations into the molecular
causes of adhesion formation have produced new concepts
of adhesion prevention. New anti-adhesion agents have
been developed and existing agents have been evaluated in
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idate previous data.
Indailyroutine,itismoreimportantthanevertobefamiliar
with the complications associated with adhesions. The neg-
ligence suits against surgeonsdue toinsufﬁcient preoperative
patient education are a problem which can affect every sur-
geon. Hence, in procedures associated with adhesion forma-
tion, surgeons should always inform their patients about the
risk of adhesion-related complications. Not only as a pre-
caution against negligence suits but also ﬁrst and foremost to
provide best possible care to our patients, we need to be fully
aware now of the extent of the problem and adopt anti-adhe-
sion strategies in our daily routine.
Methods
The PubMed database was searched using the search terms
‘adhesion AND gynecology’, ‘adhesion AND (laparoscopy
OR laparotomy)’ and ‘adhesion prevention’ with the lim-
itation on articles published in English between 1990 and
2011. The Cochrane Library was also searched for the
search term ‘adhesion’. Articles were included in the
review if the title indicated any relevance to the topic.
Statements in the articles were scrutinised by searching the
corresponding articles listed in the references sections. The
reference lists were also searched for relevant literature.
Findings
The burden of adhesions
Postoperative adhesion formation must be regarded as the
most frequent cause of small bowel obstruction (SBO). The
recurrence rate after surgical treatment of adhesive SBO is
very high [6–8]. In subsequent operations in patients with
previous lower abdominal or pelvic surgery, the risk of
inadvertent enterotomy is another important consequence
of adhesions. One study found that the overall risk for
inadvertent enterotomy in patients with previous surgery is
about 20%. During the procedure, patients with three or
more previous surgeries had a notably higher risk of
inadvertent enterotomy. This occurred in over 50% of the
cases while adhesiolysis was performed and in 30% of the
cases while the abdominal cavity was entered. Affected
patients had higher postoperative morbidity and mortality
due to inadvertent enterotomy, including small bowel
resection, intensive care admission and a longer average
hospital stay of 13 days. Therefore, identiﬁcation of high
risk patients and a systematic adhesion prevention strategy
are needed to minimise the risk of inadvertent enterotomy
in subsequent abdominal or pelvic surgery [9].
Infertility is another important consequence of adhe-
sions in gynaecology. Adhesions affect the interaction
between the Fallopian tube and the ovary. The incidence of
adhesions as a cause of infertility ranges from 20 to 40%
[10, 11].
Although chronic pelvic pain is regarded as a conse-
quence of adhesion formation, its true importance remains
uncertain [12, 13]. Women with chronic pelvic pain treated
by laparoscopic adhesiolysis compared with women treated
with diagnostic laparoscopy alone experienced no signiﬁ-
cant difference in pain relief. Nevertheless, pain decreased
after laparoscopy in both groups. Thus, the beneﬁt of lap-
aroscopic adhesiolysis alone in the treatment of chronic
pelvic pain has to be doubted and the high reformation rate
of 55 up to 100% after laparoscopic adhesiolysis must be
taken into consideration when performing adhesiolysis
alone to treat chronic pelvic pain [11, 14, 15].
Besides the adverse consequences for the patients,
adhesions are also a mounting burden on the health care
system. Based on the SCAR data, Wilson et al. [16] esti-
mated the cumulative costs of adhesion-related readmis-
sions over a 10-year period to exceed £569 million. In
Sweden, with a population of 9 million in 2004, the annual
costs of adhesion-related SBO were estimated at €39.9
million based on study data or €59.5 million when using
National Health Care Administration’s database [17]. In
the United States, the costs for adhesiolysis amounted to
$1.3 billion in 1994 [18]. Due to this great impact that
adhesions have on patients, surgeons and the health care
system, it is essential to understand how adhesions develop
and what can be done at the present to reduce their
occurrence.
Adhesion formation
Adhesion formation is a complex process inﬂuenced by
various factors and resulting in an abnormal deposition of
ﬁbrin. After trauma to the peritoneum, ﬁbrin deposition
occurs immediately, which is a normal process in perito-
neal healing. Usually, there is a balance between ﬁbrin
deposition and ﬁbrinolysis so that ﬁbrin is degraded within
a few days. However, if this process is impaired in favour
of ﬁbrin deposition, ﬁbrin strands occur and stable adhe-
sions are subsequently formed [19].
There are numerous cytokines which inﬂuence adhesion
formation both directly via the ﬁbrinolytic system and by
changing the peritoneal ﬂuid and, hence, the peritoneal
healing environment [20]. Further studies into the molec-
ular mechanisms of adhesion formation are essential to the
development of future pharmacological anti-adhesion
agents. To date, a number of studies have demonstrated the
efﬁcacy of various pharmacological approaches to adhe-
sion prevention in animals [21–24]. In humans, however,
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effective pharmacological anti-adhesion agent [25, 26].
Further research into new uses of such pharmacological
agents in humans is awaited.
In addition to this purely pharmacological approach,
other recent studies have revealed important co-factors
which play a role in adhesion formation and could theo-
retically be targeted in daily practice. Several animal
studies of adhesion formation have demonstrated a pivotal
role for the carbon dioxide pneumoperitoneum in laparos-
copy. The high pressure of the pneumoperitoneum leads to
hypoxia in the peritoneal mesothelial cells [27]. Hypoxia
inﬂuences adhesion formation in different ways [28, 29].
Diamond et al. found increased proliferation and decreased
apoptosis in ﬁbroblasts from adhesion tissue compared to
ﬁbroblasts from normal peritoneum, where hypoxia leads
to an increased rate of apoptosis. Hence, by inﬂuencing
apoptosis and proliferation in ﬁbroblasts, hypoxia in
adhesion tissue during laparoscopy may be an important
contributing factor to adhesion reformation after laparo-
scopic adhesiolysis [30]. In a rodent model, hypoxia-
induced adhesion formation was decreased by adding 3%
oxygen to the carbon dioxide pneumoperitoneum [31].
Laparoscopy was long regarded as less adhesiogenic
than laparotomy due to its less invasive nature. Research,
as noted above, offers an explanation why this hypothesis
must be rejected, because the laparoscopic environment
itself unfavourably inﬂuences adhesion formation. Another
adverse effect of laparoscopy, apart from hypoxia, is des-
iccation of the peritoneum which is caused by the endo-
scopic light and dry carbon dioxide and increases adhesion
formation. Using warm humidiﬁed gas to create the
pneumoperitoneum could prevent this effect [32]. The data
comparing laparoscopy and laparotomy with regard to their
potential for adhesion formation are conﬂicting. Whereas
some authors conﬁrmed that laparoscopy was less adhesi-
ogenic than laparotomy, a comparison of the direct adhe-
sion-related readmissions found no difference between
laparoscopy and laparotomy [33–35]. However, as Ott
expressed it: ‘‘less adhesion occurrence is still a signiﬁcant
level of adhesion occurrence’’ [32].
Regardless of whether laparoscopy or laparotomy is
performed some gynaecological procedures are associated
with a higher risk of adhesion development. Ovarian,
endometriosis or tubal surgery, myomectomy and adhesi-
olysis are procedures which lead to more adhesions,
whereas Fallopian tube sterilisation is associated with a
low risk of adhesion development [35, 36]. Adhesiolysis is
a frequently performed high risk procedure. The reforma-
tion rate of adhesions after adhesiolysis ranges from 55 to
100% with a mean incidence of 85% regardless of whether
adhesiolysis is performed by laparoscopy or laparotomy
[11]. As noted above, adhesive tissue is quite different
from normal peritoneal tissue and reacts differently to
adverse inﬂuences like hypoxia. In this case, ﬁbroblasts in
the adhesive tissue proliferate, apoptosis of the cells
decreases and molecules that inﬂuence the ﬁbrinolytic
system change so that ﬁbrinolytic activity decreases.
Hence, the high reformation rate of adhesions after
adhesiolysis might be due to the modiﬁed reaction of
adhesive tissue to adverse peritoneal environmental inﬂu-
ences [30]. Therefore, in high risk procedures like adhes-
iolysis a systematic anti-adhesion strategy should be used
and complemented with an anti-adhesion agent.
In most procedures, it is common to use electrocoagu-
lation and often suturing is needed. In a rodent model, both
techniques were identiﬁed as important co-factors in
adhesion formation if electrocoagulation of the parietal
peritoneum was used extensively. Suturing had an additive
adverse effect and led to more adhesion formation even if
only minimal coagulation was used [37].
All the above-mentioned studies and their ﬁndings are of
great importance and they underline the complexity of
adhesion formation and highlight the inﬂuence of many
different factors involved. Surgeons always be meticulous
in their surgical technique and adopt the principles of
microsurgery listed in Table 1 to reduce adhesion forma-
tion. In addition to adhering to the principles of good
surgical practice, surgeons should educate themselves
about anti-adhesion agents so they can safely use an
appropriate agent in situations where high degree of pro-
tection against adhesions is necessary. The following sec-
tions give an overview of the most common anti-adhesion
agents.
Anti-adhesion agents
Anti-adhesion agents should be used in operations which
consistently lead to adhesion formation or adhesion refor-
mation. They can broadly be divided into pharmacological
and non-pharmacological agents. Anti-adhesion agents
must always be used in combination with the principles of
microsurgery and they are not capable of compensating for
extensive tissue damage. Moreover, the available agents
can only reduce adhesion formation; they cannot entirely
eliminate their occurrence. In the last decades, considerable
research has been conducted into the complex process of
adhesion formation and various theoretical and experi-
mental approaches have been investigated to develop
appropriate pharmacological agents. Several such agents
have also been studied in humans. A number of non-
pharmacological agents were approved human use, some of
which later had to be withdrawn from the market due to
safety concerns or lack of efﬁcacy [26]. Hence, complete
adhesion prevention remains an unsolved problem and the
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following subsections provide a brief overview of previous
pharmacological and current non-pharmacological anti-
adhesion agents.
Pharmacological agents
Only a small number of pharmacological agents were
ultimately tested in humans; most agents were only tested
in animal models. The data from human trials are very
limited and were mostly published 20 or more years ago.
Based on these data, steroids and heparin cannot be rec-
ommended for the pharmacological treatment of adhesion
formation, although initially both were promising approa-
ches and were studied in humans. It was presumed that
steroids would reduce the peritoneal inﬂammatory reaction,
which enhances adhesion formation, and heparin would
prevent the ﬁbrin blood clot formation, which serves as a
matrix for adhesion formation. Unfortunately, none of
these agents proved effective in adhesion reduction [25].
Treatment with GNRH analogues to achieve hypo-oestr-
ogenism seemed another promising approach, since oest-
rogen was known to promote angiogenesis and increase
growth factor production. A recent study investigating
preoperative treatment with GNRH analogues failed to
demonstrate their efﬁcacy in reducing adhesions after
myomectomy [38]. All studies have in common that their
approaches to preventing adhesions had, of course, suc-
cessfully been tested in animals before.
Since cognitions in molecular causes of adhesion for-
mation have led to plenty of theoretical pharmacological
approaches to prevent adhesion formation, various phar-
macological agents were tested in animal models with an
efﬁcient reduction of adhesions. Decreases in adhesion
formation of over 90% were observed in a laparoscopic
mouse model using reactive oxygen species (ROS) scav-
engers, calcium channel blockers, phospholipids and
dexamethasone in addition to gentle tissue handling, 4%
oxygen in the pneumoperitoneum and low temperature
[39]. Non-steroidal anti-inﬂammatory drugs, antihista-
mines, growth factor inhibitors and vitamin E were among
the agents found to be effective in animal models. Even
honey was investigated. The list of theoretical options for
adhesion prevention is long, and hence the pharmacologi-
cal agents may be a promising approach for the future.
However, to date no effective pharmacological agent has
become available for human use [26].
Non-pharmacological agents
The approach for non-pharmacological agents is to sepa-
rate the injured tissue from the surrounding organs and the
abdominal wall throughout the time of peritoneal healing,
i.e. the critical time for adhesion formation. Anti-adhesion
agents can be categorised into two groups: site-speciﬁc
agents forming mechanical or gel barriers and broad-cov-
erage ﬂuid agents [40]. A problem encountered with the
ﬁrst two agents is the necessity to decide intraoperatively
where adhesions are likely to occur and, consequently,
where to place the agents. The decision may be easy to take
when there is only one injured site, as in myomectomy, but
may be much more difﬁcult in surgical patients with severe
endometriosis. Thus, in the latter case, ﬂuid agents are
appropriate which are injected in the peritoneal cavity and
remain there for a limited period of time. Due to these
differences between agents, it is important for every
surgeon to be familiar with the main characteristics of
anti-adhesion agents and the limitations to their use.
Table 1 Steps to reduce
adhesions, from [36]
• Carefully handle tissue with ﬁeld enhancement (magniﬁcation) techniques
• Focus on planned surgery and, if any secondary pathology is identiﬁed, question the risk/beneﬁt of
surgical treatment before proceeding
• Perform diligent haemostasis but ensure diligent use of cautery
• Reduce cautery time and frequency and aspirate aerosolised tissue following cautery
• Excise tissue—reduce fulguration
• Reduce duration of surgery
• Reduce pressure and duration of pneumoperitoneum in laparoscopic surgery
• Reduce risk of infection
• Reduce drying of tissues (limit heat and light)
• Use frequent irrigation and aspiration in laparoscopic and laparotomic surgery
• Limit use of sutures and choose ﬁne non-reactive sutures
• Avoid foreign bodies—such as materials with loose ﬁbres
• Minimise the use of dry towels or sponges in laparotomy
• Use starch- and latex- free gloves in laparotomy
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Mechanical barriers Interceed
  (Gynecare, Ethicon, a
Johnson & Johnson Company, Somerville, NJ, USA): In-
terceed
  is an oxidised regenerated cellulose membrane
placed over a suture or a deperitonealised area. No sutures
are required to keep Interceed
  in place; slight moistening
after positioning a single layer will make it adhere to the
injured site, where it is absorbed within 4 weeks [41]. In-
terceed
  has been shown to be effective in various studies,
and signiﬁcantly reduces adhesion formation even in
severe endometriosis [42]. Efﬁcacy is limited if complete
haemostasis is not achieved, though a modiﬁcation of In-
terceed
 , TC 7, was effective in a rodent model even in the
presence of blood. Nevertheless, in practice, it is necessary
to achieve meticulous haemostasis, as recommended by the
manufacturer, before applying Interceed
 , because other-
wise adhesion reduction will not be achieved [41, 43].
Interceed
  can be used in laparoscopy easily [44].
Sepraﬁlm
  (Genzyme, Cambridge, MA, USA) Sepra-
ﬁlm
 : is a hyaluronate-carboxymethyl cellulose mem-
brane, which is placed over a suture or an injured area
without stitches and remains in place for 7 days. In contrast
to Interceed
  no loss of efﬁcacy in the presence of blood
has been reported. Several studies have demonstrated the
efﬁcacy of Sepraﬁlm
  mainly in general surgery, espe-
cially bowel surgery [45]. Sepraﬁlm
  is safe with the
limitation that there is a risk of anastomotic leaks if a
suture of a fresh bowel anastomosis is wrapped with it [46].
In gynaecological surgery, the efﬁcacy of Sepraﬁlm
  has
also been demonstrated for some procedures [47, 48] but it
is not easy to use in all procedures. Sepraﬁlm
  is fragile
and therefore difﬁcult to handle particularly in laparoscopy.
However, some authors have successfully used Sepraﬁlm
 
in laparoscopy [46, 49].
Gel barriers SprayShield
 /SprayGel
  (Covidien Bio-
Surgery, Waltham, MA, USA): SprayShield
  is a synthetic
polyethylene glycol solution which is sprayed over the
affected area where it remains for approximately 5–7 days.
After that period, it is degraded and absorbed. It consists of
two components which react immediately on contact with
the tissue to form an adherent layer. One of the components
contains a blue food colourant, so there is an intraoperative
visualisation of where SprayShield
  was used [50, 51].
Efﬁcacy data are available only for the earlier formulation
of SprayShield
 , SprayGel
 . However, the two agents
differ only in minor details, including a modiﬁcation of the
polyethylene glycol, the use of methylene blue in Spray-
Gel
  and faster absorption of SprayShield
 . In the case of
myomectomy a reduction of adhesion formation was
demonstrated for SprayGel
 , but only a small number of
patients were investigated [52]. Further research is needed
to evaluate the efﬁcacy of SprayShield
  in multicentre
randomised controlled trials.
Intercoat
 /Oxiplex/AP (FzioMed, Inc., San Luis
Obispo, CA, USA): Intercoat
  is an absorbable gel com-
posed of polyethylene oxide and sodium carboxymethyl
cellulose. Functioning as a mechanical barrier during the
healing process, Intercoat
  is applied as a single layer at
the end of the procedures. Since most of the available anti-
adhesion agents were difﬁcult to use in laparoscopy,
Intercoat
  was developed especially for laparoscopic use.
Randomised clinical trials of Intercoat
  in laparoscopic
adnexal surgery and endometriosis surgery have demon-
strated the agent’s safety and efﬁcacy [53, 54].
Hyalobarrier Gel
  (Fidia Advanced Biopolymers,
Abano Terme, Italy): Hyalobarrier gel is a highly viscous
auto-crosslinked hyaluronate used to separate organs and
tissue after surgery. The use of hyaluronic acid agents may
decrease adhesion formation and prevent the deterioration
of pre-existing adhesions [25].
CoSeal
  (Baxter Healthcare Corporation, Deerﬁeld, IL,
USA): CoSeal
  is a resorbable hydrogel consisting of two
polyethylene glycol polymer solutions which are mixed
together when applied during surgery. The technology is
similar to that seen with SprayShield
  but in CoSeal
  the
polyethylene glycol esters have a different isomer struc-
ture. CoSeal
  is long available for preventing adhesions in
cardiac surgery where its efﬁcacy has already been proved.
First researches in women undergoing myomectomy
demonstrated safety and efﬁcacy of CoSeal
  in abdomi-
nopelvic surgery [40, 55].
Broad-coverage ﬂuid agents
Adept
  (Icodextrin 4% solution; Baxter Healthcare, Deer-
ﬁeld, IL, USA): Adept
  is a clear solution containing
icodextrin at a concentration of 4%. Icodextrin is an a-1-4-
linked glucose polymer and is responsible for the longer
absorption time of Adept
  compared to the previously used
crystalloid instillates like lactated Ringer’s solution, which
is rapidly resorbed by the peritoneum and therefore not
suitable for adhesion prevention. At the end of a procedure,
1,000 ml of Adept
  is instilled into the abdominal cavity.
Instillates separate the injured tissue by hydroﬂotation and
should stay in the abdominal cavity during the ﬁrst days
after surgery. Adept
  is absorbed by the lymphatic system
within 4 days and is metabolised by alpha-amylase to
lower molecular weight oligosaccharides. In a large ran-
domised controlled trial Adept
  showed signiﬁcantly
higher adhesion reduction compared with lactated Ringer’s
solution. An adverse effect of Adept
  is the labial or vulval
swelling which mostly resolves after a short period.
Adept
  is contraindicated in patients with allergy to
cornstarch-based polymers, maltose or isomaltose
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in all Adept
  is a safe, effective and affordable anti-
adhesion agent [56, 57].
Conclusion
Adhesions are an important problem in surgery and have to
be seen as an inevitable risk of abdominal and pelvic
procedures. Knowing the consequences which come along
with adhesions is important for every surgeon. Adhesions
are the subject of successful medico-legal claims, mostly
due to intraoperative events such as bowel injury. Insufﬁ-
cient preoperative patient education about the risk of
adhesion formation and intraoperative complications
associated with adhesions is an important reason for suc-
cessful lawsuits. Thus, every patient who undergoes pro-
cedures which can lead to adhesion formation or can be
complicated by adhesions should be informed about the
associated complications like infertility, small bowel
obstruction, chronic pelvic pain and bowel injury [58].
Recent research into the patient’s awareness in a Ger-
man women’s university hospital has demonstrated that at
present \50% of patients, undergoing procedures with a
high risk of adhesion formation, were made aware about
this risk prior to surgery. In the UK, the percentage of
informed patients was even lower with 27 and 8.5%,
respectively. It was assumed that one reason for this dif-
ference between the German hospital and the UK hospitals
could be the way of getting informed consent. In the UK
hospitals, no written form was used for the consent process
so the surgeons might forget to mention adhesions more
often. Nevertheless, in the German hospital, despite the fact
that adhesions were a part of the written informed consent
form, the percentage of informed patient was also not
adequate. An additional written informed consent form
where adhesion formation and their related complications
are described could be a more effective way to point out
the impact of adhesions. If this additional form would be
part of the regular patient educations, neither the surgeons
would forget to mention it nor the patients would be una-
ware of this important issue. The main source of patient
information about adhesions is their physicians, therefore,
the pre-operation discussion is the most powerful resource
for patients education that we can use [59, 60].
A further remarkable ﬁnding of one of the above-men-
tioned research was that only 8% of the patients (5% in the
UK, respectively) were aware of possibilities for preven-
tion and therapy of adhesions. Hence, it is important for
every surgeon to adopt anti-adhesion strategies in their
daily routine especially when adhesions are expected and
could affect future fertility and procedures, so they are able
to inform their patients adequate about the different
possibilities of adhesion prevention strategies. Another
recent research into the awareness of adhesions in German
hospitals has demonstrated that surgeons are interested in
the topic and are well informed about adhesion formation,
but that adhesion prevention strategies are nonetheless not
widely used. Uncertainty as to whether an agent is effective
or not is an important reason for the reserved use of anti-
adhesion agents [61].
At present the costs for the available anti-adhesion
agents are not reimbursed by the health system regularly
which might be due to concerns about the efﬁcacy. When
considering a possible reimbursment of anti-adhesion
agents the cost of an anti-adhesion agent has to be set
against the extensive costs associated with adhesion-related
complications like, for example, prolongation of operations
in further surgeries, readmissions due to complications or
diagnosis and treatment of impaired fertility. By sensitising
our patients for the important issue of adhesion develop-
ment and strategies to avoid adhesions, a higher demand
for adhesion prophylaxis by patients will arise and this
could potentially lead to reimbursment by the health sys-
tem 1 day.
The ideal anti-adhesion agent needs to be efﬁcient, safe,
easy to use and cost effective. Wilson developed a model
for the cost effectiveness of an anti-adhesion agent based
on the data from the SCAR studies. It is postulated that an
agent which costs €130 and could reduce the adhesion-
related readmissions about 25% in one year in the UK
could save more than €40 million over a 10-year period
[62]. Therefore it is necessary to take anti-adhesion agents
and the economic data on their usage into consideration to
reduce the burden on the health care system [40].
There is a growing literature with inconclusive data on
the efﬁcacy of anti-adhesion agents. This is an enormous
problem for the surgeon. The Cochrane Menstrual Disor-
ders and Subfertility Group reviewed barrier agents as well
as ﬂuid and pharmacological agents for adhesion preven-
tion tested in randomised controlled trials. Not all the
currently available agents were included in the review and
reliable statements regarding efﬁcacy were only possible
for agents that have been available for a long time. Of the
above-mentioned agents, only Interceed
  and Sepraﬁlm
 
have been studied with regard to efﬁcacy. Adept
  and
SprayShield
  were not assessable due to the limited data
available. Pregnancy rate or pain relief was not used as
endpoints in most studies, though it is precisely the eval-
uation of these clinical outcome parameters that deﬁnes the
true success of adhesion prevention [25, 63]. Other recent
research directly compared the most common anti-adhe-
sion agents and demonstrated that the reduction in adhesion
formation obtained with the most common agents was
unsatisfactory. This shows once more that, despite the
studies in a rodent model, further research on the available
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concerns in daily routine [64].
To date, only a small number of the various available
anti-adhesion agents have been studied in randomised
controlled trials. In the future, it will be necessary to test
more agents in large trials with endpoints such as preg-
nancy rates or decreasing incidence of adhesive SBO [63].
A consistent study design is necessary to enable compari-
son of studies in systematic reviews. Although large-scale
blinded randomised controlled trials are difﬁcult to con-
duct, they are important for validating the efﬁcacy of anti-
adhesion agents. At present, it is difﬁcult to determine the
extent to which an agent is effective. This could be a
challenge for the future. Knowing the real efﬁcacy of an
agent will make it easier for surgeons to choose the
appropriate agent in their daily routine. Whereas the
available agents have been demonstrated to effectively
adhesion formation in clinical studies, none of them are
able to reduce adhesion formation to a minimum. To
achieve this, in combination with good surgical technique,
will be the aim in the development of anti-adhesion agents
in the future.
Further research will reveal new insights into the path-
ophysiology of adhesion formation and lead us to fully
understand how adhesions form, what processes inﬂuence
them and which patients will develop them. The possible
combination of mechanical barriers and pharmacological
agents is another promising ﬁeld for future research.
The Expert Adhesion Working Party of the European
Society of Gynaecological Endoscopy (ESGE) in 2007
published guidelines summarising the actions to reduce
adhesions that should be adopted by all surgeons to fulﬁl
their duty of care to their patients (Table 2).
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